ETFELA: Difference between revisions
Content deleted Content added
No edit summary |
No edit summary |
||
| Line 28: | Line 28: | ||
'''N-Ethyl-N-(2,2,2-trifluoroethyl)lysergamide''' ('''ETFELA''') is an [[structural analog|analog]] of [[lysergic acid diethylamide]] (LSD) first synthesised by Jason C Parrish as part of the research team led by [[David E. Nichols]]. In studies ''in vitro'', it was found to be slightly more potent than LSD itself.<ref>Nichols DE. Structure-activity relationships of serotonin 5-HT2A agonists. ''WIREs Membr. Transp. Signal'' 2012; 1(5):559-579. {{doi|10.1002/wmts.42}}</ref><ref>Nichols DE. Chemistry and structure–activity relationships of psychedelics. In Behavioral Neurobiology of Psychedelic Drugs; Halberstadt AL, Vollenweider FX, Nichols DE. Springer 2017. pp 1-43. {{doi|10.1007/7854_2017_475}}</ref> |
'''N-Ethyl-N-(2,2,2-trifluoroethyl)lysergamide''' ('''ETFELA''') is an [[structural analog|analog]] of [[lysergic acid diethylamide]] (LSD) first synthesised by Jason C Parrish as part of the research team led by [[David E. Nichols]]. In studies ''in vitro'', it was found to be slightly more potent than LSD itself.<ref>Nichols DE. Structure-activity relationships of serotonin 5-HT2A agonists. ''WIREs Membr. Transp. Signal'' 2012; 1(5):559-579. {{doi|10.1002/wmts.42}}</ref><ref>Nichols DE. Chemistry and structure–activity relationships of psychedelics. In Behavioral Neurobiology of Psychedelic Drugs; Halberstadt AL, Vollenweider FX, Nichols DE. Springer 2017. pp 1-43. {{doi|10.1007/7854_2017_475}}</ref> |
||
==See also== |
|||
* [[ECPLA]] |
|||
== References == |
== References == |
||
Revision as of 07:42, 25 November 2019
 | |
| Clinical data | |
|---|---|
| Other names | LA-CH2CF3 |
| Identifiers | |
| |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C20H22F3N3O |
| Molar mass | 377.403 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| |
N-Ethyl-N-(2,2,2-trifluoroethyl)lysergamide (ETFELA) is an analog of lysergic acid diethylamide (LSD) first synthesised by Jason C Parrish as part of the research team led by David E. Nichols. In studies in vitro, it was found to be slightly more potent than LSD itself.[1][2]
See also
References
- ^ Nichols DE. Structure-activity relationships of serotonin 5-HT2A agonists. WIREs Membr. Transp. Signal 2012; 1(5):559-579. doi:10.1002/wmts.42
- ^ Nichols DE. Chemistry and structure–activity relationships of psychedelics. In Behavioral Neurobiology of Psychedelic Drugs; Halberstadt AL, Vollenweider FX, Nichols DE. Springer 2017. pp 1-43. doi:10.1007/7854_2017_475
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |